NRx Pharmaceuticals (NRXP) has repaid the remaining $5.4M balance sheet debt to Anson Funds through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2M to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/17/25
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/16/25
- NRx Pharmaceuticals’ KETAFREE ANDA Acceptance: A Milestone for Market Position and Revenue Growth
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/15/25
- Vanguard Total Stock Market ETF (VTI) Daily Update—12/12/25